Calliditas Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Calliditas Therapeutics has a total shareholder equity of SEK334.8M and total debt of SEK939.5M, which brings its debt-to-equity ratio to 280.6%. Its total assets and total liabilities are SEK1.9B and SEK1.5B respectively.
Key information
280.6%
Debt to equity ratio
kr939.51m
Debt
| Interest coverage ratio | n/a |
| Cash | kr973.73m |
| Equity | kr334.81m |
| Total liabilities | kr1.52b |
| Total assets | kr1.86b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0A5R's short term assets (SEK1.3B) exceed its short term liabilities (SEK407.1M).
Long Term Liabilities: 0A5R's short term assets (SEK1.3B) exceed its long term liabilities (SEK1.1B).
Debt to Equity History and Analysis
Debt Level: 0A5R has more cash than its total debt.
Reducing Debt: 0A5R's debt to equity ratio has increased from 0% to 280.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0A5R has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0A5R has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.